Edesa Biotech organizacji Gotówka na akcję

Jaka jest wartość Gotówka na akcję organizacji Edesa Biotech?

Wartość Gotówka na akcję organizacji Edesa Biotech, Inc. to 1.34

Jaka jest definicja Gotówka na akcję?

Gotówka na akcję to gotówka firmy podzielona przez akcje spółki.

Cash per share, sometimes called the cash share ratio, is the total cash per share. Cash on hand is reported on the balance sheet. Cash per share is calculated by dividing cash on hand by the total number of shares. Cash per share is the percentage of a firm's share price that is immediately accessible for spending. Cash per share consists of cash and short-term investments. It is money that a firm has on hand and does not come from borrowing or financing activities.

When a firm has a high cash per share, significant percentage of its assets is in a very liquid form. This can indicate economic uncertainty and unwillingness to invest given the current economic climate. High levels of cash per share can indicate that a firm is performing well and is able to reinvest in itself but high cash per share does not always indicate overall financial strength.

Gotówka na akcję firm w Health Care sektor na NASDAQ w porównaniu do Edesa Biotech

Czym się zajmuję organizacja Edesa Biotech?

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.

Firmy z gotówka na akcję podobne do Edesa Biotech